Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Yoshihisa Nasa"'
Autor:
Yuji Kawahara, Kouichi Tanonaka, Takuya Daicho, Mikio Nawa, Ryo Oikawa, Yoshihisa Nasa, Satoshi Takeo
Publikováno v:
Journal of Pharmacological Sciences, Vol 99, Iss 1, Pp 95-104 (2005)
Ketamine and xylazine are routinely used for measurement of hemodynamics of mice and rats by echocardiography. The anesthetic agents produce low heart rate (HR) in the animals, which may result in misleading data in the hemodynamic profiles of the sm
Externí odkaz:
https://doaj.org/article/1420264b3d6c4e7d9a8f81a9d8e6bc7e
Autor:
Satoshi Takeo, Takuya Daicho, Yoshihisa Nasa, Akito Tanoue, Kouichi Tanonaka, Gozoh Tsujimoto, Chihiro Hosoda, Norio Takagi, Ryo Oikawa
Publikováno v:
Cardiovascular Research. 87:187-194
Aims By examining vasopressin V1a receptor (V1aR) knockout (KO) mice, we previously found that the V1aR is critically involved in the regulation of normal blood pressure. The present study was undertaken to elucidate the role of the V1aR in salt-indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d6c446e2827f96de4f45ee89913984a
https://doi.org/10.1093/cvr/cvq034
https://doi.org/10.1093/cvr/cvq034
Autor:
Hitoshi Okamura, Tetsuya Adachi, Yoshihisa Nasa, Gozoh Tsujimoto, Akito Tanoue, Taka-aki Koshimizu, Toyoki Mori, Tomoyuki Kuwaki, Yasushi Kiyono, Yuji Kawahara, Toshiki Tanaka, Satoshi Takeo, Ryo Oikawa
Publikováno v:
Proceedings of the National Academy of Sciences. 103:7807-7812
Arginine-vasopressin (AVP) is a hormone that is essential for both osmotic and cardiovascular homeostasis, and exerts important physiological regulation through three distinct receptors, V1a, V1b, and V2. Although AVP is used clinically as a potent v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe1e1f3449f25ebdee09d5e770e3be8
https://doi.org/10.1073/pnas.0600875103
https://doi.org/10.1073/pnas.0600875103
Autor:
Yoshihisa Nasa, Satoshi Takeo, Takuya Daicho, Ryo Oikawa, Kouichi Tanonaka, Mikio Nawa, Yuji Kawahara
Publikováno v:
Journal of Pharmacological Sciences, Vol 99, Iss 1, Pp 95-104 (2005)
Ketamine and xylazine are routinely used for measurement of hemodynamics of mice and rats by echocardiography. The anesthetic agents produce low heart rate (HR) in the animals, which may result in misleading data in the hemodynamic profiles of the sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785caf3f2ea5cf08dc7e2776baf307b4
http://www.sciencedirect.com/science/article/pii/S1347861319321383
http://www.sciencedirect.com/science/article/pii/S1347861319321383
Autor:
Yoshihisa Nasa, Tadaichi Kitamura, Taka-aki Koshimizu, Takashi Tomabechi, Chihiro Hosoda, Sayuri Oshikawa, Susanna Cotecchia, Akito Tanoue, Gozoh Tsujimoto, Hitomi Shinoura, Shinya Fukuda, Ryo Oikawa, Satoshi Takeo
Publikováno v:
Molecular Pharmacology. 67:912-922
To study the functional role of individual alpha1-adrenergic (AR) subtypes in blood pressure (BP) regulation, we used mice lacking the alpha1B-AR and/or alpha1D-AR with the same genetic background and further studied their hemodynamic and vasoconstri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a41fa350f99028d7b2b82a230b5ecaba
https://doi.org/10.1124/mol.104.007500
https://doi.org/10.1124/mol.104.007500
Autor:
Akito Tanoue, Gozoh Tsujimoto, Satoshi Takeo, Yoshihisa Nasa, Taka-aki Koshimizu, Katsushi Shibata
Publikováno v:
Trends in Endocrinology and Metabolism. 14:107-113
Alpha(1)-adrenoceptors (ARs) mediate some of the main actions of the natural catecholamines, epinephrine and norepinephrine, and have a crucial role in the regulation of arterial blood pressure. Since alpha(1)-AR was subdivided into three subtypes (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecbea77591d116adedb5de54d1c9703f
https://doi.org/10.1016/s1043-2760(03)00026-2
https://doi.org/10.1016/s1043-2760(03)00026-2
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 305:97-105
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme (ACE) inhibitors in the treatment of chronic heart failure (CHF). The present study was undertaken to determine whether sam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5609987f320438bdd0f444f8748b715e
https://doi.org/10.1124/jpet.102.042747
https://doi.org/10.1124/jpet.102.042747
Autor:
Hiroyuki Yoshida, Toshiyuki Maki, Satoshi Takeo, Masaya Takahashi, Kouichi Tanonaka, Yoshihisa Nasa
Publikováno v:
British Journal of Pharmacology. 134:150-160
Inhibition of the renin-angiotensin system (RAS) improves symptoms and prognosis in heart failure. The experimental basis for these benefits remains unclear. We examined the effects of inhibition of ACE or blockade of angiotensin II type 1 (AT1) rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80c720040c7f4542f39e568882247bb0
https://doi.org/10.1038/sj.bjp.0704219
https://doi.org/10.1038/sj.bjp.0704219
Autor:
Satoshi Takeo, Kouichi Tanonaka, Yukiko Kaizuka, Hiroshi Kajiwara, Yasuo Nakajima, Yumiko Ohya, Yoshihisa Nasa
Publikováno v:
Drug Development Research. 51:20-28
Blockade of sodium overload during ischemia and reperfusion plays an important role in cardioprotection. The present study was undertaken to determine whether or not a novel cyclohexane dicarboximide derivative, ST-6, which reveals sodium channel blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd67afc8c23360857fb85487baca221
https://doi.org/10.1002/1098-2299(20000901)51:1<20::aid-ddr3>3.0.co
https://doi.org/10.1002/1098-2299(20000901)51:1<20::aid-ddr3>3.0.co
Autor:
Takahiro Igarashi, Satoshi Takeo, Atsushi Sanbe, Kouichi Tanonaka, Isamu Kamano, Fuminari Yamaguchi, Yoshihisa Nasa, Toshiyuki Maki, Ken-ichiro Kawana, Eigyoku Gen, Yoko Fujimoto
Publikováno v:
British Journal of Pharmacology. 126:1585-1592
The effects of long-term treatment with trandolapril, an angiotensin I-converting enzyme inhibitor, on exercise capacity of rats with chronic heart failure (CHF) following coronary artery ligation were examined. CHF was developed by 8 weeks after the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d4d295956787f352b8a500e7c645119
https://doi.org/10.1038/sj.bjp.0702471
https://doi.org/10.1038/sj.bjp.0702471